122 related articles for article (PubMed ID: 17867385)
1. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells.
Weigel NL
Nutr Rev; 2007 Aug; 65(8 Pt 2):S116-7. PubMed ID: 17867385
[No Abstract] [Full Text] [Related]
2. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
3. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
[TBL] [Abstract][Full Text] [Related]
4. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Antagonists Suppress Immunotherapy in Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):569. PubMed ID: 27102077
[TBL] [Abstract][Full Text] [Related]
6. Nur77 suppression facilitates androgen deprivation-induced cell invasion of prostate cancer cells mediated by TGF-β signaling.
Wu J; Sun H; Yang X; Sun X
Clin Transl Oncol; 2018 Oct; 20(10):1302-1313. PubMed ID: 29594945
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D in Prostate Cancer.
Ahn J; Park S; Zuniga B; Bera A; Song CS; Chatterjee B
Vitam Horm; 2016; 100():321-55. PubMed ID: 26827958
[TBL] [Abstract][Full Text] [Related]
8. Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.
Godoy AS; Chung I; Montecinos VP; Buttyan R; Johnson CS; Smith GJ
Am J Physiol Endocrinol Metab; 2013 Jun; 304(11):E1131-9. PubMed ID: 23548616
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
El-Sayed IY; Daher A; Destouches D; Firlej V; Kostallari E; Maillé P; Huet E; Haidar-Ahmad N; Jenster G; de la Taille A; Abou Merhi R; Terry S; Vacherot F
Cancer Lett; 2017 Dec; 410():100-111. PubMed ID: 28935391
[TBL] [Abstract][Full Text] [Related]
13. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D and prostate cancer.
Stewart LV; Weigel NL
Exp Biol Med (Maywood); 2004 Apr; 229(4):277-84. PubMed ID: 15044710
[TBL] [Abstract][Full Text] [Related]
16. Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells.
Smith KW; Thompson PD; Rodriguez EP; Mackay L; Cobice DF
Biochem Biophys Res Commun; 2019 Nov; 519(3):579-584. PubMed ID: 31537382
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
18. Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling.
Yang Y; Ikezoe T; Zheng Z; Taguchi H; Koeffler HP; Zhu WG
Int J Oncol; 2007 Sep; 31(3):593-600. PubMed ID: 17671686
[TBL] [Abstract][Full Text] [Related]
19. Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
Bianchini D; de Bono JS
Eur J Cancer; 2011 Sep; 47 Suppl 3():S189-94. PubMed ID: 21943974
[No Abstract] [Full Text] [Related]
20. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
